SCHEMBL12394342

SCHEMBL12394342

Cc1ccccc1[PH](=O)C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
ACHE P22303 2/20 0.39
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA7 P43166 1/20 0.37
CA9 Q16790 1/20 0.37
ALDH1A1 P00352 4/20 0.33
HSD17B10 Q99714 1/20 0.31
CYP3A4 P08684 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
CASR P41180 1/20 0.31
PBRM1 Q86U86 1/20 0.31
TNKS2 Q9H2K2 1/20 0.31
GABRA1 P14867 1/20 0.30
GABRB2 P47870 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
PDK1 Q15118 1/20 0.30
PDK2 Q15119 1/20 0.30
PDK3 Q15120 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12667246 0.76 ALDH1A1 (0.41) TSHRCA1CA2CA7CA9
SCHEMBL1188527 0.75 TSHR (0.47) TSHRACHECA1CA2CA7
SCHEMBL20231791 0.73 TSHR (0.45) TSHRACHECA1CA2CA7
SCHEMBL4433607 0.72 PTGS2 (0.37) ALDH1A1HSD17B10TDP1CYP2A6
SCHEMBL5187678 0.71 TSHR (0.43) TSHRACHECA1CA2CA7
SCHEMBL230855 0.71 TSHR (0.43) TSHRACHECA1CA2CA7
SCHEMBL29080964 0.71 TSHR (0.43) TSHRACHECA1CA2CA7
Potassium SCHEMBL6755124 0.70 TSHR (0.41) TSHRACHECA1CA2CA7
Hydrochloric Acid SCHEMBL11774243 0.70 TSHR (0.41) TSHRACHECA1CA2CA7
SCHEMBL19895699 0.70 TSHR (0.41) TSHRACHECA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130267714-A1 BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS SOLVIAS AG (CH) 2013-10-10 US disclosed
US-8450501-B2 Bidentate chiral ligands for use in catalytic asymmetric addition reactions SOLVIAS AG (CH) 2013-05-28 US disclosed
US-8415488-B2 Bidentate secondary phosphine oxide chiral ligands for use in asymmetric addition reactions SOLVIAS AG (CH) 2013-04-09 US disclosed
US-8008529-B2 Chiral ligands used in transition metal catalysts for asymmetric addition reactions especially hydrogenation SOLVIAS AG (CH) 2011-08-30 US disclosed
US-20110118482-A1 BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS SOLVIAS AG 2011-05-19 US disclosed
US-20110098485-A1 BIDENTATE SECONDARY PHOSPHINE OXIDE CHIRAL LIGANDS FOR USE IN ASYMMETRIC ADDITION REACTIONS SOLVIAS AG (CH) 2011-04-28 US disclosed
US-20090171114-A1 Chiral Ligands Used in Transition Metal Catysts for Asymmetric Addition Reactions Especially Hydrogenation SOLVIAS AG (CH) 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098485-A1 BIDENTATE SECONDARY PHOSPHINE OXIDE CHIRAL LIGANDS FOR USE IN ASYMMETRIC ADDITION REACTIONS H1-2, PHOSPHO1, H1-0 TSHR 1741/4885ACHE 4433/4885CA1 173/4885
US-20090171114-A1 Chiral Ligands Used in Transition Metal Catysts for Asymmetric Addition Reactions Especially Hydrogenation HRH3, HRH4, HRH1 TSHR 1571/4885ACHE 2822/4885CA1 135/4885
US-20130267714-A1 BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS C1R, PNISR, CBR1 TSHR 512/4885ACHE 1920/4885CA1 2000/4885
US-20110118482-A1 BIDENTATE CHIRAL LIGANDS FOR USE IN CATALYTIC ASYMMETRIC ADDITION REACTIONS H1-2, H1-0, C1R TSHR 1127/4885ACHE 4187/4885CA1 349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.